Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Monday 28 March, 2022

SkinBioTherapeutics

Directorate Change

RNS Number : 1525G
SkinBioTherapeutics PLC
28 March 2022
 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Proposed Directorate Appointments

 

28th March 2022 - SkinBioTherapeutics plc (AIM: SBTX), a life Science business focusing on skin health, today announces the proposed appointments of Manprit Singh Randhawa as full time Chief Financial Officer (CFO) and Danielle Bekker as non executive director, subject to the completion of normal regulatory due diligence being carried out by the Company's AIM Nominated Adviser.

 

Chief Financial Officer

 

Manprit Singh Randhawa most recently worked as CFO at the leading educational technology firm, Juniper Education Group. Previously, he was CFO at Smoothwall and before then, at Onbone Oy, a medical technology business. He has in-depth knowledge in scale-up and growth environments as well as AIM experience having acted as Group Financial Controller of global radiation detection technology company, Kromek Group Plc.  He is a qualified chartered accountant and started his career at Deloitte.

 

It is proposed that Manprit will be taking over from Doug Quinn, SkinBioTherapeutics' current part-time CFO, upon Nominated Adviser confirmation of his appointment.

 

Non Executive Director

 

Danielle Bekker is to join the SkinBioTherapeutics Board as a non executive director. She brings experience in direct to consumer marketing, including a focus on the use of influencers and digital media in the FMCG (Fast Moving Consumer Goods) space having launched her own direct to consumer beverage business. She has a core set of skills that the Board believes will be invaluable to the Company as it commercialises its first product, AxisBiotix-Ps™, and subsequent products e.g. acne. She also has strong supply chain management and governance skills, having worked with big corporates as well as ecommerce skills developed by founding her own business in the drinks industry.

 

 

 Martin Hunt, Chairman of SkinBioTherapeutics, said:

"We have changed the CFO position from part time to full time role to reflect the new commercial path of the business. We are delighted to welcome Manprit to SkinBioTherapeutics at this exciting commercial stage of the Company's development, following the launch of AxisBiotix-Ps™. His financial expertise in scale-up environments at both private and AIM listed companies makes him an excellent fit for the full time CFO role and we are looking forward to him joining the team."  

 

He added, "We also look forward to welcoming Danielle to the Board. We have deliberately chosen a NED with FMCG experience since this brings a fresh outlook and varied experience, as well as her extensive network, to our commercialisation plans. She has considerable skills in how to sell to consumers using digital marketing, including influencers, which we believe will be invaluable as we accelerate the sales of AxisBiotix-Ps as well as driving our long-term ambitions of launching into other consumer areas."

 

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis / Jonjo Cordey

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGZGZFRNGGZZM

a d v e r t i s e m e n t